Class / Patent application number | Description | Number of patent applications / Date published |
544344000 | Tricyclo ring system having the diazine ring as one of the cyclos | 7 |
20120253042 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES - A process for preparing amides by reacting a primary amine and a primary alcohol in the presence of a Ruthenium complex to generate the amide and molecular hydrogen. Primary amines are directly acylated by equimolar amounts of alcohols to produce amides and molecular hydrogen (the only byproduct) in high yields and high turnover numbers. Also disclosed are processes for hydrogenation of amides to alcohols and amines; hydrogenation of organic carbonates to alcohols; hydrogenation of carbamates or urea derivatives to alcohols and amines; amidation of esters; acylation of alcohols using esters; coupling of alcohols with water and a base to form carboxylic acids; dehydrogenation of beta-amino alcohols to form pyrazines and cyclic dipeptides; and dehydrogenation of secondary alcohols to ketones. These reactions are catalyzed by a Ruthenium complex which is based on a dearomatized PNN-type ligand of formula A1 or precursors thereof of formulae A2 or A3. | 10-04-2012 |
20130178625 | P 2 X 4 RECEPTOR ANTAGONIST - A compound having the following formula (II) or a pharmacologically acceptable salt thereof is used as a P2X | 07-11-2013 |
20130289275 | PROCESS FOR THE PREPARATION OF PRAZIQUANTEL - The present disclosure describes a novel, cost-effective process for preparation of a 4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino-[2,1-a]isoquinoline derivatives. Specifically, it discloses a process for the preparation of the anthelmintic drug praziquantel through the use of a novel intermediate, 2-[(2,2-dimethoxyethyl)benzyl amino]-N-phenethylacetamide. This present disclosure also describes a novel crystalline form of 4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinoline. | 10-31-2013 |
544345000 | Three or more ring hetero atoms in the tricyclo ring system | 4 |
20090306381 | Mono Amine and Diamine Derivatives of CL-20 - The invention describes the synthesis of novel mono-amine and di-amine derivatives of hexa-nitro-hexaazaisohex-awurtzitane (CL-20). The synthesis is effected by the novel use of fluoroacylating compounds to protect the secondary amine groups of acylated precursors to CL-20 against nitrolysis. In so doing the mono-amine and di-amine derivatives of CL-20 are rendered and which in turn may be subsequently utilised as intermediates to generate further novel derivatives with differing physical and chemical properties to the parent compound. Formula (I), wherein:— X═H, and Y═H or NO | 12-10-2009 |
544346000 | Ring nitrogen is shared by two of the cyclos (e.g., ergot, alkaloids, etc.) | 3 |
20110263855 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS - Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P | 10-27-2011 |
20140039188 | NOVEL ISO-ERGOLINE DERIVATIVES - Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 02-06-2014 |
20140073790 | NOVEL FLUOROERGOLINE ANALOGS - Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 03-13-2014 |